Technology is disrupting the development of new medications and treatments, and fueling a rise in the booming biotech industry. Cancer and autoimmune disorders specialist Sutro Biopharma is just the latest to test the public markets, making its market debut at the end of September. Bill Newell, CEO of Sutro Biopharma gave his outlook for the company.